Crescent Biopharma (CBIO) Non-Current Assets (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Non-Current Assets data on file, last reported at $3.6 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $3.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 million (up 889.53% YoY), and the FY2025 annual result was $3.6 million, up 347.48% from the prior year.
• Non-Current Assets fell to $3.6 million in Q1 2026 per CBIO's latest filing, from $3.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $4.0 million in Q1 2022 and troughed at $52320.0 in Q3 2024.
• A 5-year average of $2.0 million and a median of $1.5 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets plunged 95.61% in 2024, then jumped 6983.33% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $1.1 million in 2022, then soared by 39.22% to $1.5 million in 2023, then sank by 46.71% to $813000.0 in 2024, then jumped by 347.48% to $3.6 million in 2025, then slipped by 1.95% to $3.6 million in 2026.
• Business Quant data shows CBIO's Non-Current Assets at $3.6 million in Q1 2026, $3.6 million in Q4 2025, and $3.7 million in Q3 2025.